UNICANCER
263
50
100
120
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
7.2%
19 terminated/withdrawn out of 263 trials
86.3%
-0.2% vs industry average
32%
83 trials in Phase 3/4
6%
7 of 120 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (263)
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma
Role: collaborator
Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis
Role: lead
Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008
Role: lead
Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)
Role: lead
Evolution of the Therapeutic Care in Ovarian Cancer From 2011
Role: lead
Blood Biomarkers Based Screening for HPV-driven OPC
Role: lead
Liver-directed Chemotherapy After Surgery of Liver Metastases of Colorectal Cancer in Patients With High Risk of Recurrence of Their Disease
Role: lead
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib
Role: lead
Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients
Role: lead
Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment
Role: lead
Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.
Role: lead
Arm Swelling Occurence in Breast Cancer Patients With Nodal Radiotherapy: Impact of Informing Them of AI-predicted Risk
Role: lead
Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients
Role: lead
Personalized Medicine for Advanced Biliary Cancer Patients
Role: lead
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
Role: lead
Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases
Role: lead
Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.
Role: lead
Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer
Role: collaborator
Evaluation of Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma
Role: collaborator
Adjuvant Palbociclib in Elderly Patients With Breast Cancer
Role: collaborator